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Figure 1. Overall survival.
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Nivolumab is a member of the new class of immunother-
apies, so called “checkpoint” inhibitors, with tremendous
activity in solid tumours as well as Hodgkins lymphoma.1
Case Report: Here we describe the outcome of a 25 yo
woman diagnosed with Hodgkin’s lymphoma (HL, classical
nodular) in 2009 after presenting with neck lymphadenop-
athy. She was treated but relapsed in October of 2010 and
received salvage chemotherapy followed by autologous stem
cell transplantation.
In November 2011, she relapsed again and achieved par-
tial remission after multiple rounds of therapies including
brentuximab vedotin. In October 2013, she underwent an
allogeneic stem cell transplant (ASCT) with fludarabine and
busulfan conditioning from a matched unrelated donor. Her
transplant course was complicated by mild chronic GVHD
presenting as nausea, vomiting and joint pains. She also
developed an atypical “chronic” GVHD manifested as inter-
mittent hemibody sensory loss, tingling, and weakness with
periodic confusions which could only be controlled by low
dose daily prednisone.
At day+590 post ASCT, she relapsed classical nodular
sclerosing HL. At a second institution, she began Nivolumab
at 3mg/Kg intravenously. Fourteen days after her first dose,
she developed grade III transaminitis and was placed on
prednisone 2mg/kg for 7 day but 24 days after the Nivolumab
dose, she presented to our ER with RUQ abdominal pain,
pruritis, jaundice and grade IV transaminitis with bilirubin of
10 which subsequently peaked to 31 (Figure 1). A workup for
infectious etiology (EBV, hepatitis, CMV, Adenovirus and
HHV6) was negative. An abdominal ultrasound was negative
for VOD/SOS. A liver biopsy was consistent with aGVHD as
evidenced by loss of interlobular bile ducts, mild cen-
trilobular perivenular fibrosis, increased intrasinusoidal
kupffer cells, and hepatocyte injury (Figure 2). She also
developed severe low TSH/free T4 levels suggestive of central
hypothyroidism. She was restarted on steroids at 2mg/kg but
after 2 weeks, developed hepatorenal syndrome and hypo-
tension. Hemodislysis/Plasmaphoresis followed by extracor-
poreal photophoresis was initiated but unfortunately her
condition rapidly deteriorated. She ultimately succumbed to
hypotension with disseminated intravascular coagulation
and multi-organ failure.
Conclusion: To our knowledge this is the first case of
documented acute GVHD induced by an anti-PD1 antibody
following ASCT. The use of immune checkpoint inhibitors
after ASCT should be examined carefully.
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Background: The demethylating agent 5-azacytidine (AZA)
has proven its efficacy as treatment for myelodysplasticsyndrome and acute myeloid leukemia. In addition, AZA can
demethylate FOXP3 intron 1 (FOXP3i1) leading to the gener-
ation of regulatory T cells (Tregs).
Objective: We investigated the impact of AZA on xenogeneic
graft-versus-host disease (xGVHD) in a humanized murine
model of transplantation, and described the impact of the
drug on human T cells in vivo.
Methods: In order to induce xGVHD, human peripheral
blood mononuclear cells (huPBMC) were administered
intravenously in NOD-scid IL-2Rgnull (NSG) mice.
Results: AZA successfully improved both survival
(p<0.0001) and xGVHD scores (p<0.0001). Further, AZA
significantly decreased human T-cell proliferation as well as
INF-g and TNF-a serum levels, and reduced the expression of
GRANZYME B and PERFORIN 1 by cytotoxic T cells. In addi-
tion, AZA administration significantly increased the function,
proliferation and frequency of Tregs through demethylation
of FOXP3i1 and higher secretion of IL-2 by conventional T
cells due to IL2 gene promoter site 1 demethylation. Inter-
estingly, among AZA-treated mice surviving the acute phase
of xGVHD, there was an inverse correlation between the
presence of Tregs and signs of chronic GVHD. Finally, Tregs
harvested from the spleen of AZA-treated mice were sup-
pressive and stable over time since they persisted at high
frequency in secondary transplant experiments.
Conclusion: These findings emphasize a potential role for
AZA as prevention or treatment of GVHD.593
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Background: Chronic graft-versus-host disease (cGVHD) is
the most common cause of morbidity and mortality after
allogeneic stem cell transplant (alloSCT) for hematologic
malignancies. While 50% of patients respond to
